Tc-99m-NTP 15-5 assessment of the early therapeutic response of chondrosarcoma to zoledronic acid in the Swarm rat orthotopic model

Article English OPEN
Miot-Noirault, E. ; David, E. ; Vidal, A. ; Peyrode, C. ; Besse, S. ; Dauplat, M-M. ; Heymann, M-F. ; Gouin, F. ; Chezal, J-M. ; Heymann, D. ; Redini, F. (2013)
  • Publisher: BioMed Central

Background: Since proteoglycans (PGs) appear as key partners in chondrosarcoma biology, PG-targeted imaging using the radiotracer 99mTc-N-(triethylammonium)-3-propyl-[15]ane-N5 (99mTc-NTP 15-5) developed by our group was previously demonstrated to be a good single-photon emission computed tomography tracer for cartilage neoplasms. We therefore initiated this new preclinical study to evaluate the relevance of 99mTc-NTP 15-5 imaging for the in vivo monitoring and quantitative assessment of chondrosarcoma response to zoledronic acid (ZOL) in the Swarm rat orthotopic model.\ud Findings: Rats bearing chondrosarcoma in the orthotopic paratibial location were treated by ZOL (100 μg/kg, subcutaneously) or phosphate-buffered saline, twice a week, from day 4 to day 48 post-tumor implantation. 99mTc-NTP 15-5 imaging was performed at regular intervals with the target-to-background ratio (TBR) determined. Tumor volume was monitored using a calliper, and histology was performed at the end of the study. From day 11 to day 48, mean TBR values ranged from 1.7 ± 0.6 to 2.3 ± 0.6 in ZOL-treated rats and from 2.1 ± 1.0 to 4.9 ± 0.9 in controls. Tumor growth inhibition was evidenced using a calliper from day 24 and associated to a decrease in PG content in treated tumor tissues (confirmed by histology).\ud Conclusions: This work demonstrated two proofs of concept: (1) biphosphonate therapy could be a promising therapeutic approach for chondrosarcoma; (2) 99mTc-NTP 15-5 is expected to offer a novel imaging modality for the in vivo evaluation of the extracellular matrix features of chondrosarcoma, which could be useful for the follow-up and quantitative assessment of proteoglycan ‘downregulation’ associated to the response to therapeutic attempts.
  • References (13)
    13 references, page 1 of 2

    1. World Health Organization: Cartilage tumors. In Pathology and Genetics of Tumours of Soft Tissue and Bone. Edited by Fletcher CDM, Unni KK, Mertens F. Lyon: IARC; 2002:234-257 [Kleihues P, Sobin LH (Series Editors): World Health Organization Classification of Tumors].

    2. Velasco CR, Colliec-Jouault S, Redini F, Heymann D, Padrines M: Proteoglycans on bone tumor development. Drug Discov Today 2010, 13-14:553-560.

    3. Miot-Noirault E, Gouin F, Vidal A, Rapp M, Maublant J, Askienazy S, Chezal JM, Heymann D, Redini F, Moins N: First preclinical imaging of primary cartilage neoplasm and its local recurrence using 99mTc-NTP 15-5 radiotracer. J Nucl Med 2009, 50:1541-1547.

    4. Onishi AC, Hincker AM, Lee FY: Surmounting chemotherapy and radioresistance in chondrosarcoma: molecular mechanisms and therapeutic targets. Sarcoma 2011, 2011:381564.

    5. Moriceau G, Ory B, Gobin B, Verrecchia F, Gouin F, Blanchard F, Redini F, Heymann D: Therapeutic approach of primary bone tumours by bisphosphonates. Curr Pharm Des 2010, 16:2981-2987.

    6. Gouin F, Ory B, Rédini F, Heymann D: Zoledronic acid slows down rat primary chondrosarcoma development, recurrent tumor progression after intralesional curretage and increases overall survival. Int J Cancer 2006, 119:980-984.

    7. Streitbuerger A, Henrichs M, Ahrens H, Lanvers-Kaminzky C, Gouin F, Gosheger G, Hardes J: Cytotoxic effect of clodronate and zoledronate on the chondrosarcoma cell lines HTB-94 and CAL-78. Int Orthop 2011, 35:1369-1373.

    8. Grimaud E, Damiens C, Rousselle AV, Passuti N, Heymann D, Gouin F: Bone remodelling and tumor grade modifications induced by interactions between bone and swarm rat chondrosarcoma. Histol Histopathol 2002, 17:1103-1111.

    9. Odri GA, Dumoucel S, Picarda G, Battaglia S, Lamoureux F, Corradini N, Rousseau J, Tirode F, Laud K, Delattre O, Gouin F, Heymann D, Redini F: Zoledronic acid as a new adjuvant therapeutic strategy for Ewing's sarcoma patients. Cancer Res 2010, 70:7610-7619.

    10. Montella L, Addeo R, Faiola V, Cennamo G, Guarrasi R, Capasso E, Mamone R, Caraglia M, Del Prete S: Zoledronic acid in metastatic chondrosarcoma and advanced sacrum chordoma: two case reports. J Exp Clin Cancer Res 2009, 28:7.

  • Similar Research Results (2)
  • Metrics
    0
    views in OpenAIRE
    0
    views in local repository
    1
    downloads in local repository

    The information is available from the following content providers:

    From Number Of Views Number Of Downloads
    White Rose Research Online - IRUS-UK 0 1
Share - Bookmark